TY - JOUR
T1 - Role of allogeneic stem cell transplantation in multiple myeloma
AU - Kumar, Shaji
PY - 2008/4
Y1 - 2008/4
N2 - Multiple myeloma remains incurable despite the use of high-dose therapy and autologous stem cell transplantation and the introduction of novel agents with high response rates. The use of an uncontaminated stem cell graft and the presence of a graft-versus-myeloma effect led to the use of allogeneic stem cell transplantation in myeloma, and it has been part of the therapeutic armamentarium for more than a decade. Early results were discouraging due to high transplantation-related mortality and high rates of graft-versus-host disease. More recently, better supportive care, increasing experience with this modality and its complications, use of reduced-intensity conditioning regimens, and its use earlier in the course of disease have led to improved outcomes. Patients with high-risk genetic and biochemical features do poorly with conventional therapies, and allogeneic transplantation offers the potential for long-term disease control.
AB - Multiple myeloma remains incurable despite the use of high-dose therapy and autologous stem cell transplantation and the introduction of novel agents with high response rates. The use of an uncontaminated stem cell graft and the presence of a graft-versus-myeloma effect led to the use of allogeneic stem cell transplantation in myeloma, and it has been part of the therapeutic armamentarium for more than a decade. Early results were discouraging due to high transplantation-related mortality and high rates of graft-versus-host disease. More recently, better supportive care, increasing experience with this modality and its complications, use of reduced-intensity conditioning regimens, and its use earlier in the course of disease have led to improved outcomes. Patients with high-risk genetic and biochemical features do poorly with conventional therapies, and allogeneic transplantation offers the potential for long-term disease control.
UR - http://www.scopus.com/inward/record.url?scp=47149091698&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=47149091698&partnerID=8YFLogxK
U2 - 10.1007/s11899-008-0015-9
DO - 10.1007/s11899-008-0015-9
M3 - Review article
C2 - 20425453
AN - SCOPUS:47149091698
SN - 1558-8211
VL - 3
SP - 99
EP - 106
JO - Current Hematologic Malignancy Reports
JF - Current Hematologic Malignancy Reports
IS - 2
ER -